Monomeric igg1 fc molecules displaying unique fc receptor interactions that are exploitable to treat inflammation-mediated diseases

mAbs

Volumn 6, Issue 5, 2014, Pages 1201-1210

  Ying, Tianlei ^a,b   Feng, Yang ^b   Wang, Yanping ^b,c   Chen, Weizao ^b   Dimitrov, Dimiter S ^b  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Geneva Foundation   (United States)

Author keywords

ADCC; Chronic inflammation; Fcg receptors; FcRn; Monomeric fc

Indexed keywords

FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIIA; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MESOTHELIN; MONOMERIC IMMUNOGLOBULIN G1 FC FRAGMENT; NEONATAL FC RECEPTOR; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CHRONIC INFLAMMATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOLECULAR SIZE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; PROTEIN TARGETING; U937 CELL LINE; WILD TYPE;

EID: 84913543666     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29835     Document Type: Article

References (39)

1. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/ nri2155
2. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10.1038/ nri2206
3. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20:685-91; PMID:19896358; http://dx.doi.org/ 10.1016/j.copbio.2009.10.011
4. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601
5. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/ pnas.0508123103
6. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS. Fcfusion proteins and FcRn: structural insights for lon-ger-lasting and more effective therapeutics. Crit Rev Biotechnol 2013;In press; PMID:24156398; http://dx. doi.org/10.3109/07388551.2013.834293
7. Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4:1015-28; PMID:22837174; http://dx.doi.org/10.1002/emmm.201201379
8. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415-6; PMID:21785279; http://dx.doi. org/10.4161/mabs.3.5.17334
9. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, Fc gRI. J Immunol 2011; 186:2699-704; PMID:21325219; http://dx.doi.org/ 10.4049/jimmunol.1003526
10. Thepen T, Huhn M, Melmer G, Tur MK, Barth S. Fcgamma receptor 1 (CD64), a target beyond cancer. Curr Pharm Des 2009; 15:2712-8; PMID:19689341; http://dx.doi.org/10.2174/138161209788923967
11. Thepen T, van Vuuren AJ, Kiekens RC, Damen CA, Vooijs WC, van De Winkel JG. Resolution of cutaneous inflammation after local elimination of macrophages. Nat Biotechnol 2000; 18:48-51; PMID:10625390; http://dx.doi.org/10.1038/71908
12. Tur MK, Huhn M, Thepen T, Stocker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 2003; 63:8414-9; PMID:14679004
13. Nuutila J. The novel applications of the quantitative analysis of neutrophil cell surface FcgammaRI (CD64) to the diagnosis of infectious and inflammatory diseases. Curr Opin Infect Dis 2010; 23:268-74; PMID:20407370; http://dx.doi.org/10.1097/QCO. 0b013e32833939b0
14. Hulse KE, Woodfolk JA. Targeting allergen to Fc gammaRI: a strategy to treat allergic disease? Curr Opin Allergy Clin Immunol 2008; 8:547-52; PMID:18978470; http://dx.doi.org/10.1097/ACI. 0b013e32831665d2
15. Mancardi DA, Albanesi M, Jonsson F, Iannascoli B, Van Rooijen N, Kang X, England P, Daeron M, Bruhns P. The high-affinity human IgG receptor FcgRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013; 121:1563-73; PMID:23293080; http://dx.doi.org/ 10.1182/blood-2012-07-442541
16. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Mart-?nez-Mart-?nez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/ 10.1126/science.1144603
17. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/ 10.1038/nbt.1553
18. Ying T, Chen W, Gong R, Feng Y, Dimitrov DS. Soluble monomeric IgG1 Fc. J Biol Chem 2012; 287:19399-408; PMID:22518843; http://dx.doi.org/ 10.1074/jbc.M112.368647
19. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25; PMID:19018092; http://dx.doi.org/ 10.1182/blood-2008-09-179754
20. Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, Dimitrov DS. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009; 8:1113-8; PMID:19417159; http://dx.doi.org/10.1158/1535-7163.MCT-08-0945
21. Miller KL, Duchemin AM, Anderson CL. A novel role for the Fc receptor gamma subunit: enhancement of Fc gamma R ligand affinity. J Exp Med 1996; 183:2227-33; PMID:8642332; http://dx.doi.org/10.1084/ jem.183.5.2227
22. Li P, Jiang N, Nagarajan S, Wohlhueter R, Selvaraj P, Zhu C. Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16a) binding to IgG ligands. J Biol Chem 2007; 282:6210-21; PMID:17202140; http://dx.doi. org/10.1074/jbc.M609064200
23. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005; 11:3814-20; PMID:15897581; http:// dx.doi.org/10.1158/1078-0432.CCR-04-2304
24. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496:445-55; PMID:23619691; http://dx.doi.org/ 10.1038/nature12034
25. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008; 7:2924-32; PMID:18790773; http://dx.doi.org/ 10.1158/1535-7163.MCT-08-0554
26. Tur MK, Huhn M, Jost E, Thepen T, Br ummendorf TH, Barth S. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int J Cancer 2011; 129:1277-82; PMID:21077160; http:// dx.doi.org/10.1002/ijc.25766
27. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011; 17:6398-405; PMID:22003067; http://dx.doi.org/10.1158/1078-0432.CCR-11-0487
28. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I. Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010; 16:1894-903; PMID:20215554; http://dx.doi.org/10.1158/ 1078-0432.CCR-09-2980
29. Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012; 899:1-26; PMID:22735943; http://dx.doi.org/ 10.1007/978-1-61779-921-1-1
30. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7:21-39; PMID:18097458; http:// dx.doi.org/10.1038/nrd2399
31. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc frag-ment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; http://dx.doi.org/10.1038/ 35018508
32. Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 2010; 107:604-9; PMID:20080725; http://dx.doi.org/10.1073/pnas. 0908590107
33. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001; 276:16469-77; PMID:11297532; http://dx.doi.org/ 10.1074/jbc.M100350200
34. Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fc g receptor I and its implication in high affinity g-immunoglobulin binding. J Biol Chem 2011; 286:40608-13; PMID:21965667; http:// dx.doi.org/10.1074/jbc.M111.257550
35. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j. cell.2010.03.014
36. van Vuuren AJ, van Roon JA, Walraven V, Stuij I, Harmsen MC, McLaughlin PM, van de Winkel JG, Thepen T. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J Immunol 2006; 176:5833-8; PMID:16670289; http:// dx.doi.org/10.4049/jimmunol.176.10.5833
37. van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, Thepen T, van de Winkel JG. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis Rheum 2003; 48:1229-38; PMID:12746896; http://dx.doi. org/10.1002/art.10940
38. Ying T, Ju TW, Wang Y, Prabakaran P, Dimitrov DS. Interactions of IgG1 CH2 and CH3 Domains with FcRn. Front Immunol 2014; 5:146; PMID:24765095; http://dx.doi.org/10.3389/fimmu.2014.00146
39. Ying T, Gong R, Ju TW, Prabakaran P, Dimitrov DS. Engineered Fc based antibody domains and fragments as novel scaffolds. [epub ahead of print]. Biochim Biophys Acta 2014; PMID:24792384; http://dx.doi.org/ 10.1016/j.bbapap.2014.04.018